Medscape. May 09, 2013
The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a "rational basis" for treatment decisions.
Those decisions are now "complex" because a group of treatment
options for metastatic disease has emerged in a short period of time,
according to a press release issued at AUA 2013 Annual Scientific
Meeting, held in San Diego, California.
Read the full Medscape report
(Free sign-up may be required)
Wednesday, May 15, 2013
Testosterone Benefits Hypogonadal Men With Type 2 Diabetes
Medscape. May 08, 2013.
PHOENIX — Testosterone replacement reverses insulin resistance in hypogonadal men with type 2 diabetes, preliminary data suggest. The findings, from a randomized trial in 81 men, were reported by Paresh Dandona, MD, PhD, head of the division of endocrinology, diabetes, and metabolism at the University of Buffalo, State University of New York, at the American Association of Clinical Endocrinologists 2013 Scientific & Clinical Congress last week.
"Hypogonadotropic hypogonadism [HH] in type 2 diabetes is a factor related to insulin resistance and may be contributing to it. Administration of testosterone over a period of 6 months largely reverses that state of insulin resistance," said Dr. Dandona.
Read the full Medscape report
(Free sign-up may be required)
PHOENIX — Testosterone replacement reverses insulin resistance in hypogonadal men with type 2 diabetes, preliminary data suggest. The findings, from a randomized trial in 81 men, were reported by Paresh Dandona, MD, PhD, head of the division of endocrinology, diabetes, and metabolism at the University of Buffalo, State University of New York, at the American Association of Clinical Endocrinologists 2013 Scientific & Clinical Congress last week.
"Hypogonadotropic hypogonadism [HH] in type 2 diabetes is a factor related to insulin resistance and may be contributing to it. Administration of testosterone over a period of 6 months largely reverses that state of insulin resistance," said Dr. Dandona.
Read the full Medscape report
(Free sign-up may be required)
AUA Issues New Guidelines on PSA Screening
Medscape. May 03, 2013
New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.
Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action.
Read the full Medscape report
(free sign-up may be required)
New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.
Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action.
Read the full Medscape report
(free sign-up may be required)
Thursday, May 2, 2013
Decreasing Infections from a Prostate Biopsy
In today's video from Dr. Gerald Chodak, he discusses the risks of infection from having a prostate biopsy and what measures can be taken to minimize those risks.
Monday, April 29, 2013
Supplements don't help with prostate cancer
NEW YORK (Reuters Health) -
Despite dietary supplements being popular among prostate cancer patients, a new review of past research says they are not effective treatments for the disease.
Pulling together data from eight randomized controlled trials - considered the gold standard of medical research, researchers found non-herbal dietary supplements and vitamins didn't significantly change the severity of people's cancers.
"The main message would be that no miraculous supplement for (prostate cancer) exists," wrote Dr. Paul Posadzki, the review's lead author from the Korea Institute of Oriental Medicine in Daejeon, in an email to Reuters Health.
Sickle cell disease accounts for many priapism cases
Andrew M. Seaman | Reuters – Thu, Apr 25, 2013
NEW YORK (Reuters Health) - Thanks to commercials for erectile dysfunction
drugs, men know to seek medical attention for "erections lasting more
than four hours," but a new study suggests a blood disorder is the cause
of many prolonged erections.
While the condition - formally known as priapism - is rare, researchers report in The Journal of Urology that between 14 percent and 30 percent of cases that show up in U.S. emergency rooms are men with sickle-cell disease.
"I would say what
the paper is telling us is that sickle-cell disease is still responsible
for the bulk of the visits for priapism," said Dr. Gregory Broderick, professor of urology at the Mayo Clinic in Jacksonville, Florida, who was not involved in the study.
Prostate cancer screening for older men 'unlikely'
NHS Choices (Wed April 17, 2013)
There is wide coverage of new research that argues that routine screening could reduce deaths from prostate cancer, with BBC News, The Daily Telegraph and the Daily Mail all reporting the story. This controversial study is likely to reignite the debate about whether routine screening for prostate cancer does more harm than good.
Read the full NHS report
There is wide coverage of new research that argues that routine screening could reduce deaths from prostate cancer, with BBC News, The Daily Telegraph and the Daily Mail all reporting the story. This controversial study is likely to reignite the debate about whether routine screening for prostate cancer does more harm than good.
Read the full NHS report
Subscribe to:
Posts (Atom)